ClarivateTM Analytics released the 2022 update of its Journal Citation Reports©, including the much anticipated 2021 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2021 impact factor of 30.083, up from the 2020 score of 25.083.
Geneva, Switzerland, 28 June 2022 – The latest release reveals that the Journal of Hepatology continues to climb with an impressive 20% increase in one year and more than doubling in the past five years. To date, the 2021 score is the highest the Journal of Hepatology has achieved.
The Journal of Hepatology has performed exceptionally, yet again in receiving its impact factor for 2021 of 30.083. The EASL Governing Board congratulates the editorial team, its board, and the Journal office, the unfailing peer reviewers, and the authors for this brilliant achievement. The articles published in this journal impact considerably on research and clinical practice in our field, and so it continues to attract top-notch writing. We also express our gratitude to Prof. Paolo Angeli and his team, and the editors-in-chiefs, and editorial boards, from today and yesterday. They have all contributed to today’s achievement as a top-tier journal,
said Prof. Thomas Berg, Secretary General of EASL.
The Journal has once again confirmed its very high ranking in the field of hepatology and gastroenterology, increasing its impact factor in the past year. I have always believed that maintaining this place and these high standards would be difficult, but we have proven that we can do it. I really want to thank all of the people who contributed and who are still contributing to this great result, starting with the Senior and Associate Editors and all the Reviewers. You have all performed superbly in selecting the highest quality articles. It is my strong desire to give my special thanks to the members of the Editorial Office for their commitment and professionalism in this very difficult period. Our aim is to always improve our performance and focus on what we consider fundamental, that is a very active interaction with all the members of our community: scientists, physicians, patients, caregivers, and decision-makers in healthcare. This is our legacy, and this is what we are doing and will continue to do,
said Prof. Paolo Angeli, Editor-in-Chief of the Journal of Hepatology.
The record high score, together with similar increases in other metrics, reaffirms the continued commitment of EASL, to provide the scientific community with a high-quality publication that delivers impactful content in liver research. An impact factor is a measure of a journal’s significance in an academic field. It considers the frequency with which the average article in a journal is cited in a given year. This data helps indicate a journal’s relative importance when compared to other publications in the same field. The Journal of Hepatology publishes 12 issues a year and covers a wide variety of topics in clinical and basic research within the field.
About the Journal of Hepatology
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. It is a monthly, English language, peer-reviewed journal. First published in 1985 as the official journal of EASL, it provides an international forum for the publication of original articles, reviews and letters to the Editor describing basic laboratory, translational, and clinical investigations in hepatology. All articles undergo a rigorous peer review and are selected based on the originality of the findings, the superior quality of the work described, and the clarity of presentation. Visit the website of the Journal of Hepatology.
About the European Association for the Study of the Liver (EASL)
EASL, the European Association for the Study of the Liver, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2022, EASL serves 4,800 members. EASL engages globally with all stakeholders in the field of hepatology, worldwide. Our aim is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in this field. We advocate for the benefit of patients and advise European and national health authorities. EASL runs topical conferences, schools, and related educational meetings. Our journals, the Journal of Hepatology and JHEP Reports, provide an international forum for the publication of original articles, reviews, and letters to the Editor, describing the latest science in hepatology. Our eLearning hub, EASL Campus, offers more than 6,200 resources on hepatology and liver research.
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect, and commercialise their inventions, using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.